查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420994

失眠市场（治疗类型：苯二氮平类药物、非苯二氮平类药物、抗忧郁剂、食慾素拮抗剂、褪黑素拮抗剂、设备等）- 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Insomnia Market (Treatment Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10个工作天内

价格

失眠市场 - 报告范围

TMR 关于全球失眠市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了该期间全球失眠市场的收入2017-2031年，以2023年为基准年，2031年为预测年。报告中也提供了2023年至2031年全球失眠市场的年复合成长率（CAGR %）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解失眠市场。

市场概况
2023年市场价值 38 亿美元
2031 年市场价值 64 亿美元
CAGR 6%

该报告深入研究了全球失眠市场的竞争格局。全球失眠市场的主要参与者已被确定，并且每位参与者都已根据各种属性进行了分析。公司概况、财务状况、近期发展和 SWOT 是本报告中介绍的全球失眠市场参与者的属性。

目录

第 1 章：执行摘要

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 市场区隔
  • 概述
  • 市场动态
  • 2017-2031 年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 全球主要国家的疾病盛行率和发生率
  • COVID-19 大流行对该行业的影响

第 6 章：市场分析与预测：依治疗类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2017-2031
    • 苯二氮平类
    • 非苯二氮平类药物
    • 抗忧郁药
    • 食慾素拮抗剂
    • 褪黑素拮抗剂
    • 装置
    • 其他的
  • 市场吸引力：按治疗类型

第 7 章：全球市场分析与预测：按销售管道

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：2017-2031年按销售管道
    • 医院药房
    • 零售药局和药局
    • 网路药局
  • 市场吸引力：按销售管道划分

第 8 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 9 章：北美市场分析与预测

第 10 章：欧洲市场分析与预测

第 11 章：亚太市场分析与预测

第 12 章：拉丁美洲市场分析与预测

第 13 章：中东和非洲市场分析与预测

第14章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Paratek Pharmaceuticals, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Teva Pharmaceutical Industries Limited
    • Vanda Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Sanofi SA
    • Merck & Co., Inc.
    • Viatris Inc.
Product Code: TMRGL20246

Insomnia Market - Scope of Report

TMR's report on the global insomnia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global insomnia market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insomnia market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insomnia market.

Market Snapshot
Market Value in 2023US$ 3.8 Bn
Market Value in 2031US$ 6.4 Bn
CAGR6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insomnia market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global insomnia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insomnia market.

The report delves into the competitive landscape of the global insomnia market. Key players operating in the global insomnia market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global insomnia market profiled in this report.

Key Questions Answered in Global insomnia Market Report:

  • What is the sales/revenue generated by insomnia across all regions during the forecast period?
  • What are the opportunities in the global insomnia market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Insomnia Market - Research Objectives and Research Approach

The comprehensive report on the global insomnia market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global insomnia market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global insomnia market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Insomnia Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Insomnia Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. COVID-19 Pandemic Impact on Industry

6. Insomnia Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 6.3.1. Benzodiazepines
    • 6.3.2. Nonbenzodiazepines
    • 6.3.3. Antidepressants
    • 6.3.4. Orexin Antagonist
    • 6.3.5. Melatonin Antagonist
    • 6.3.6. Devices
    • 6.3.7. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Insomnia Market Analysis and Forecast, by Sales Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies and Drug Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness, by Sales Channel

8. Global Insomnia Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Insomnia Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment Type, 2017-2031
    • 9.2.1. Benzodiazepines
    • 9.2.2. Nonbenzodiazepines
    • 9.2.3. Antidepressants
    • 9.2.4. Orexin Antagonist
    • 9.2.5. Melatonin Antagonist
    • 9.2.6. Devices
    • 9.2.7. Others
  • 9.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies and Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Sales Channel
    • 9.5.3. By Country

10. Europe Insomnia Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2017-2031
    • 10.2.1. Benzodiazepines
    • 10.2.2. Nonbenzodiazepines
    • 10.2.3. Antidepressants
    • 10.2.4. Orexin Antagonist
    • 10.2.5. Melatonin Antagonist
    • 10.2.6. Devices
    • 10.2.7. Others
  • 10.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies and Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Sales Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Insomnia Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2017-2031
    • 11.2.1. Benzodiazepines
    • 11.2.2. Nonbenzodiazepines
    • 11.2.3. Antidepressants
    • 11.2.4. Orexin Antagonist
    • 11.2.5. Melatonin Antagonist
    • 11.2.6. Devices
    • 11.2.7. Others
  • 11.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies and Drug Stores
    • 11.3.3. Online Pharmacies
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Sales Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Insomnia Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2017-2031
    • 12.2.1. Benzodiazepines
    • 12.2.2. Nonbenzodiazepines
    • 12.2.3. Antidepressants
    • 12.2.4. Orexin Antagonist
    • 12.2.5. Melatonin Antagonist
    • 12.2.6. Devices
    • 12.2.7. Others
  • 12.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies and Drug Stores
    • 12.3.3. Online Pharmacies
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Sales Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Insomnia Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2017-2031
    • 13.2.1. Benzodiazepines
    • 13.2.2. Nonbenzodiazepines
    • 13.2.3. Antidepressants
    • 13.2.4. Orexin Antagonist
    • 13.2.5. Melatonin Antagonist
    • 13.2.6. Devices
    • 13.2.7. Others
  • 13.3. Market Value Forecast, by Sales Channel, 2017-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies and Drug Stores
    • 13.3.3. Online Pharmacies
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Sales Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Paratek Pharmaceuticals, Inc.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Treatment Type Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Sumitomo Dainippon Pharma Co., Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Treatment Type Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Teva Pharmaceutical Industries Limited
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Treatment Type Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Vanda Pharmaceuticals Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Treatment Type Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Takeda Pharmaceutical Company Limited
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Treatment Type Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Pfizer Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Treatment Type Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Sanofi S.A
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Treatment Type Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Merck & Co., Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Treatment Type Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Viatris Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Treatment Type Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 02: Global Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 03: Global Insomnia Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 05: North America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 06: North America Insomnia Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 08: Europe Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 09: Europe Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 11: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 12: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 14: Latin America Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 15: Latin America Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
  • Table 17: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Sales Channel, 2017-2031
  • Table 18: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031
  • Figure 03: Global Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 04: Global Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 05: Global Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 06: Global Insomnia Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Insomnia Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 08: North America Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 10: North America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 11: North America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 12: North America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 13: North America Insomnia Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Insomnia Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 15: Europe Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 17: Europe Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 18: Europe Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 19: Europe Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 20: Europe Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 22: Asia Pacific Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Insomnia Market Value Share Analysis, by Treatment Type 2022 and 2031
  • Figure 24: Asia Pacific Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 25: Asia Pacific Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 26: Asia Pacific Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 27: Asia Pacific Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 29: Latin America Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 31: Latin America Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 32: Latin America Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 33: Latin America Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 34: Latin America Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 36: Middle East & Africa Insomnia Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Insomnia Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 38: Middle East & Africa Insomnia Market Attractiveness Analysis, by Treatment Type, 2017-2031
  • Figure 39: Middle East & Africa Insomnia Market Value Share Analysis, by Sales Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Insomnia Market Attractiveness Analysis, by Sales Channel, 2017-2031
  • Figure 41: Middle East & Africa Insomnia Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Insomnia Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 43: Global Insomnia Market Share Analysis, by Company, 2022